Mammalian Cell Banking Market By Cell Bank Type (Master Cell Bank, Working Cell Bank); By Cell Type (CHO Cells, HEK293 Cells, BHK Cells, Hybridoma Cells, Other Mammalian Cell Lines); By Application (Monoclonal Antibody Production, Vaccine Production, Gene Therapy, Cell Therapy, Recombinant Protein Production, Research and Development); By End User (Pharmaceutical and Biotechnology Companies, Contract Development and Manufacturing Organizations, Contract Research Organizations, Academic and Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Mammalian Cell Banking Market: The Hidden Backbone of Global Biologics Manufacturing

The Global Mammalian Cell Banking Market was valued at USD 580 million in 2025 and is projected to reach USD 1.47 billion by 2032, growing at a CAGR of 14.2% during 2026–2032.

 

The mammalian cell banking market refers to the regulated process of creating, testing, preserving, and storing mammalian cell lines that are used to manufacture biologic medicines. These cell lines—such as Chinese hamster ovary (CHO), HEK293, BHK, Vero, NS0, and hybridoma cells—serve as the biological foundation for producing monoclonal antibodies, recombinant proteins, vaccines, viral vectors, and other biologic therapies. In commercial manufacturing, a two-level system is typically used: the Master Cell Bank (MCB), which is the original, fully qualified and cryogenically stored source of the production cell line, and the Working Cell Bank (WCB), which is derived from the master bank and used directly to start routine manufacturing batches. According to FDA inspection guidance, the MCB is the long-term stored source from which WCBs are created, while the WCB is the material actually used in day-to-day production.

 

This system is used to ensure consistency, safety, and reproducibility in biologic drug manufacturing. By preserving a well-characterized master source and using controlled working copies for production, manufacturers can maintain identical cell performance across multiple batches, reduce the risk of contamination or genetic drift, and meet strict regulatory requirements. In simple terms, mammalian cell banking acts as the “biological backup system” of the biopharmaceutical industry, ensuring that every dose of a biologic medicine is produced from a stable, verified, and traceable cell source.

 

Why Is Mammalian Cell Banking Becoming More Important to Biologics Manufacturing?

Mammalian cell banking is being supported by the continued importance of mammalian expression systems in commercially approved biologics. A review of biopharmaceutical approvals found that 85% of genuinely novel biopharmaceutical active ingredients examined for the relevant period were manufactured using mammalian systems. Of 107 products produced in mammalian cells, 95 products, or 89%, used CHO cells.

This concentration has direct commercial consequences. Each biologic program that advances toward clinical or commercial manufacturing requires manufacturers to maintain a reproducible biological starting source. A qualified bank may support manufacturing for years, making early control of cell identity and stability important to later batch consistency, manufacturing transfers and regulatory inspections.

The expanding biosimilar pipeline adds another layer of demand. FDA's current biosimilar database records several approvals during 2026, including Zimrixby, a rituximab biosimilar, and Garzulys, an insulin aspart biosimilar, in July 2026. Biosimilars place particular emphasis on manufacturing consistency because product quality must be controlled despite the inherent variability associated with biological production systems.

Europe is seeing similar activity. The European Medicines Agency issued 104 positive opinions for new medicines in 2025, including 41 biosimilars. Continued expansion of biologics and biosimilars increases the number of development and manufacturing programs requiring qualified cell substrates, characterization services, working banks and long-term storage.

 

Is Outsourcing Becoming More Attractive Than Maintaining Cell Banks Internally?

Cell banking creates an unusual make-or-buy decision for biotechnology companies. The physical volume of material is small, but the infrastructure required to produce, test and preserve it under regulated conditions can be expensive.

An internal program may require qualified manufacturing space, cryogenic equipment, environmental monitoring, quality oversight, controlled inventory systems and access to specialized biosafety testing. Smaller biotechnology companies may need these capabilities only periodically, making dedicated infrastructure difficult to justify.

Outsourced suppliers can combine cell-bank production, characterization, biosafety testing, release and long-term storage in one program. That reduces the number of transfers between laboratories and can simplify vendor management and documentation.

The scale of specialist providers shows how established this outsourced model has become. Charles River reports more than 2,000 cell and viral banks produced and operates nine cGMP-compliant cleanroom suites, including seven dedicated mammalian suites.

Sartorius reports more than 120 cGMP cell banks manufactured, tested and QP-released.

WuXi Biologics' current service information reports more than 980 GMP cell banks created over nine years and 19 GMP banking suites, while its broader platform links cell banking with characterization and downstream biologics development.

These figures represent supplier-specific experience rather than global market volumes, but they indicate that outsourced cell banking has developed into a sizeable specialist service business.

 

Why Does CHO Cell Banking Hold Such a Strong Commercial Position?

CHO cells have become deeply established in monoclonal antibody and recombinant protein manufacturing. Their commercial position reflects decades of regulatory precedent, process-development experience and investment in production platforms.

The published biopharmaceutical benchmark showing 95 of 107 mammalian-produced products using CHO cells illustrates the scale of that position.

This creates a large addressable banking base because each CHO program requires preservation of the production clone and controlled access to Working Cell Banks throughout manufacturing.

HEK293 occupies a different but increasingly important position. Its use in viral-vector production connects cell banking to gene therapy and other vector-dependent platforms. Charles River specifically identifies HEK293 banking for AAV, retroviral, lentiviral and other viral-vector applications.

BHK, Vero, NS0, hybridoma and other cell lines serve vaccine, antibody and specialized recombinant production requirements. The result is a market where CHO represents the established commercial base while alternative cell types create additional opportunities around vaccines, gene therapy and specialized biologic manufacturing.

 

How Is the Mammalian Cell Banking Market Structured Across Key Categories?

Division of Product-Type Revenue Between Master and Working Cell Banks

Master Cell Banks represent the largest segment, accounting for approximately 55% of the market in 2025 and around USD 319 million in revenue. The segment is expected to expand at a CAGR of approximately 13.8% during 2026–2032.

The higher current share reflects the greater characterization, documentation and long-term strategic value attached to MCB establishment. An MCB serves as the controlled source from which future production banks are derived, meaning problems at this stage can affect an entire development or commercial program.

Working Cell Banks account for approximately 45% of the market in 2025, valued at around USD 261 million, but carry a somewhat faster CAGR of approximately 14.7% during 2026–2032.

The faster WCB growth rate is consistent with expanding commercial production. Once a biologic moves from development into repeated manufacturing campaigns, additional Working Cell Banks may be needed to support production volumes, new manufacturing sites or longer commercial lifecycles. The narrowing growth-rate difference indicates that recurring manufacturing activity is becoming increasingly important alongside initial bank establishment.

 

Mammalian Cell Types Capturing the Most Revenue

CHO cells dominate the cell-type segment with approximately 48% market share in 2025, representing around USD 278 million, and are projected to grow at approximately 14.0% CAGR during 2026–2032.

Their position is closely tied to monoclonal antibodies and recombinant therapeutic proteins. The segment benefits from a large installed base of CHO-based production processes and continued development of antibody-based medicines.

HEK293 cells account for approximately 22% of the 2025 market, valued at around USD 128 million, and are expected to grow at approximately 15.2% CAGR. Their growth is faster than CHO because demand is increasingly connected to viral-vector production, gene therapy development and other biologic platforms where HEK293 has become commercially important.

BHK cells represent approximately 10% of the market and around USD 58 million in 2025, with an estimated 13.5% CAGR. Demand is concentrated in specific vaccine, recombinant protein and viral-production applications rather than across the broad antibody-manufacturing base served by CHO.

Hybridoma cells account for approximately 8% of the market, valued at around USD 46 million, and are projected to expand at approximately 12.8% CAGR. Hybridoma banking continues to serve established antibody research and production requirements, although newer recombinant antibody platforms are limiting its relative growth compared with HEK293 and other cell systems.

Other mammalian cell lines account for approximately 12%, or around USD 70 million, in 2025, with a comparatively strong 14.8% CAGR. This category captures demand from Vero, NS0, MDCK, MRC-5 and other specialized substrates used across vaccines, recombinant proteins and niche biological manufacturing processes.

The overall mix shows that CHO should continue providing the largest revenue pool, while faster growth in HEK293 and specialized cell lines broadens the market beyond traditional monoclonal antibody manufacturing.

 

Liquid Nitrogen Storage Holds the Largest Share in Cell Banking Storage Market

Liquid nitrogen storage accounts for approximately 68% of the mammalian cell banking market in 2025, valued at around USD 394 million, and is projected to grow at approximately 13.9% CAGR during 2026–2032.

Its large share reflects the long storage horizons associated with MCBs and WCBs and the industry's need to preserve production cells without continuous culture and the associated risk of biological drift. FDA inspection guidance specifically recognizes liquid nitrogen and its vapor phase as conditions generally associated with longer cell stability than approximately −70°C storage.

Mechanical freezer storage represents approximately 32% of the market in 2025, valued at around USD 186 million, and is forecast to grow faster at approximately 14.9% CAGR.

Mechanical systems can support selected intermediate, research, backup and operational storage strategies without dependence on liquid-nitrogen handling infrastructure. The faster growth rate suggests that buyers are increasingly considering mixed storage architectures rather than relying on a single preservation format, although long-term commercial cell-bank strategy continues to favor deeply cryogenic storage.

 

Which Applications Are Creating the Largest Cell-Banking Demand

Monoclonal antibody production is the largest application, accounting for approximately 42% of market revenue in 2025, or around USD 244 million, with an expected 13.8% CAGR through 2032.

The segment's leadership closely follows CHO's position in commercial biologics manufacturing. Antibody programs require stable production clones that can support development, scale-up, validation and repeated commercial manufacturing over long product lifecycles.

Vaccine production accounts for approximately 18%, or around USD 104 million, in 2025, and is projected to grow at approximately 14.5% CAGR. Vaccine demand covers multiple mammalian substrates, including Vero, BHK and other cell lines, depending on the vaccine platform.

Gene therapy represents approximately 12% of the market and around USD 70 million in 2025, but has the fastest application growth rate at approximately 17.2% CAGR. Commercial demand is being supported by viral-vector programs that require controlled producer, packaging or supporting cell substrates. HEK293's growing role in vector manufacturing strengthens the connection between this application and outsourced banking providers.

Cell therapy represents approximately 10% of the 2025 market, valued at around USD 58 million, with a similarly strong 17.0% CAGR. This segment should be interpreted around the qualified mammalian cell substrates and banking infrastructure used in applicable cell-therapy development and manufacturing workflows rather than conventional biologic production alone.

Recombinant protein production contributes approximately 10%, or USD 58 million, in 2025, and is projected to grow at approximately 13.5% CAGR. Its demand is supported by established CHO and other mammalian expression systems used where product structure or biological processing favors mammalian production.

Research and development accounts for approximately 8% of the market and around USD 46 million, expanding at approximately 12.9% CAGR. Although it is the smallest application segment, R&D activity continually feeds future commercial demand because promising research banks may ultimately progress into qualified GMP Master Cell Banks.

The difference in growth rates is commercially significant: monoclonal antibodies provide the largest existing revenue pool, while gene therapy and cell therapy are the fastest-expanding applications in the supplied forecast.

 

Which Buyers Account for the Largest Share of Cell-Banking Spending

Pharmaceutical and biotechnology companies are the largest end-user group, accounting for approximately 52% of the market in 2025 and around USD 302 million in revenue. The segment is projected to grow at approximately 14.1% CAGR during 2026–2032.

These companies ultimately own the biologic development programs and therefore carry responsibility for maintaining qualified production substrates, regardless of whether banking activities are performed internally or outsourced.

Contract Development and Manufacturing Organizations account for approximately 22% of the market, valued at around USD 128 million, and have the fastest end-user growth rate at approximately 15.3% CAGR.

This faster expansion fits the broader outsourcing trend in biologics development. CDMOs increasingly support customers from cell-line development through cell banking, upstream manufacturing and commercial supply, turning banking into part of a wider development-to-manufacturing contract.

Contract Research Organizations represent approximately 14%, or around USD 81 million, in 2025, and are projected to expand at approximately 13.9% CAGR. Their participation is particularly relevant to characterization, biosafety testing and development-stage cell-bank support.

Academic and research institutes account for approximately 12% of the market, valued at around USD 70 million, with an estimated 12.8% CAGR. This is the slowest-growing end-user category among the supplied segments, reflecting the greater commercial value associated with GMP manufacturing and regulated biologics programs than with research-only banking.

Taken together, the end-user mix indicates that commercial drug developers will continue generating the largest demand, while CDMOs are gaining share as banking becomes increasingly embedded within outsourced biologics manufacturing relationships.

 

Which Companies Are Building the Strongest Mammalian Cell Banking Portfolios?

Competition in the mammalian cell banking market increasingly depends on the breadth of services surrounding the physical bank. Major providers are combining GMP manufacturing, characterization, viral-safety testing, storage and downstream biologics development so that customers can use fewer vendors during development.

Sartorius: Sartorius provides mammalian MCB and WCB manufacturing for suspension and adherent cells through closed, single-use processes and automated vial filling. The company reports more than 120 cGMP cell banks manufactured, tested and QP-released. Its platform includes CHO and HEK293 banking, high-density options and integrated characterization, connecting cell banking with Sartorius' wider cell-line development, media and bioprocess portfolio.

Charles River Laboratories: Charles River reports more than 2,000 cell and/or viral banks produced, nine cGMP-compliant cleanroom suites and seven dedicated mammalian suites. Its mammalian capabilities include banks of up to 1,000 vials, with CHO specifically positioned for recombinant protein and monoclonal antibody manufacturing and HEK293 for viral-vector applications. The company's wider portfolio in biologics testing and characterization strengthens its position where sponsors want banking and regulatory testing managed within the same supplier network.

Merck / MilliporeSigma: Merck provides MCB and WCB manufacturing at cGMP facilities in the United States and United Kingdom and supports banks of up to 1,000 vials. Its disclosed cell-line capabilities include CHO, HEK293, MRC-5, Vero, NS0, Sp2/0 and MDCK. The breadth of this portfolio allows Merck to address antibody, vaccine, recombinant protein and other biologics programs rather than relying on one production-cell category.

WuXi Biologics: WuXi integrates cell banking into a larger end-to-end biologics development and manufacturing platform. Its current cell-banking information reports more than 980 GMP cell banks created during the past nine years, 19 GMP banking suites and services spanning MCBs, WCBs and end-of-production banks. WuXi also provides cell-line development, characterization, biosafety testing and biologics manufacturing, allowing cell banking to sit within a longer outsourced CMC program.

 

How Does the Mammalian Cell Banking Market Differ Across Regions?

North America: The United States offers one of the deepest commercial environments for mammalian cell banking because of its concentration of biotechnology development, licensed biologics and outsourced testing and manufacturing providers, and it is the largest regional market, accounting for approximately 38% market share in 2025, valued at around USD 220 million, with a projected CAGR of ~13.7% during 2026–2032.

FDA’s Purple Book, which includes FDA-licensed biological products regulated by CDER as well as allergenic, cellular and gene therapy, hematologic, and vaccine products regulated by CBER, highlights the broad scope of regulated biologics activity that depends on controlled manufacturing systems and, for mammalian-derived products, qualified production substrates. This expanding regulatory landscape is further reinforced by the FDA’s growing biosimilar list, which has continued to add new approvals, including multiple entries during the first seven months of 2026, reflecting sustained expansion of the commercial biologics base.

In North America, the opportunity therefore extends well beyond the initial creation of cell banks. FDA expectations around storage control, traceability, characterization, and backup storage locations generate ongoing demand for repository management, replacement Working Cell Banks, and lifecycle testing throughout a product’s commercial lifespan.

Europe: Europe combines a mature biologics manufacturing base with harmonized regulatory expectations for biological production systems, accounting for approximately 28% market share in 2025, valued at around USD 162 million, and is projected to grow at a CAGR of ~13.9% during 2026–2032. ICH requirements covering cell-substrate characterization and viral safety create a similar quality framework across major European biologics markets.

The region's biosimilar activity is particularly relevant, with the EMA recording 41 biosimilar positive opinions among 104 positive opinions for new medicines in 2025. Biosimilars, recombinant biologics, and advanced therapies all increase demand for traceable starting materials and documented manufacturing consistency, while Europe also hosts major banking, testing, and biomanufacturing operations from suppliers including Sartorius, Merck, and other specialized service providers.

Asia-Pacific: Asia-Pacific is becoming increasingly important as more biologics manufacturing capacity is built within the region, accounting for approximately 24% market share in 2025 and valued at around USD 139 million, with a projected CAGR of ~15.8% during 2026–2032. Singapore provides one of the clearest official examples. Singapore's Economic Development Board states that the country has more than 60 biopharmaceutical manufacturing plants, with industry output exceeding S$18 billion in 2023, and that eight of the world's top 10 biopharmaceutical companies operate manufacturing facilities there.

Capacity continues to expand, with AbbVie’s Singapore investment adding 24,000 litres of biologics drug-substance capacity to its manufacturing network, underscoring the region’s growing role in global biologics production. China has also developed large outsourced biologics platforms, with WuXi Biologics’ dedicated cell-banking, characterization and manufacturing infrastructure illustrating how more banking work can now be performed within Asia rather than being transferred to North American or European providers. Overall, the regional opportunity is being driven by both domestic biotechnology development and multinational companies expanding Asian manufacturing capacity closer to major healthcare markets.

Latin America: Accounting for approximately 6% market share in 2025, valued at around USD 35 million, the region is expected to grow at a CAGR of ~13.5% during 2026–2032, supported by investments in vaccines, biologics, and technology transfer that are strengthening infrastructure for future demand.

Brazil is the largest example, where the Ministry of Health identifies Bio-Manguinhos/Fiocruz as a major vaccine producer and continues to support partnerships focused on vaccine technology transfer and domestic manufacturing. In 2025, Fiocruz and Biological E signed a cooperation agreement covering vaccine research, technology transfer, and production capabilities. Brazil also produces the yellow fever vaccine domestically through Bio-Manguinhos/Fiocruz, which the Ministry of Health describes as the world’s largest producer of that vaccine. For mammalian cell banking suppliers, the longer-term opportunity depends on more Latin American programs moving upstream into biological drug-substance production, where qualified cell substrates, testing, and storage become essential components of local manufacturing.

Middle East & Africa: The current commercial cell-banking base is smaller, accounting for approximately 4% of the market in 2025 and valued at around USD 23 million, but policy support for local biological manufacturing may create additional long-term opportunities, with the region expected to grow at a CAGR of ~12.9% during 2026–2032.

The Partnership for African Vaccine Manufacturing has set a vision for the continent to produce 60% of the vaccines it needs by 2040, a target also referenced in WHO's framework for strengthening local production. While this goal should not be interpreted as a direct forecast for the mammalian cell banking market—since vaccines can be produced using multiple biological systems—it still carries important implications for upstream infrastructure. Any expansion into locally produced vaccines or biologics that rely on Vero, BHK, HEK, or other mammalian substrates will require corresponding capabilities for qualified cell-bank establishment, biosafety testing, and long-term storage. As a result, the regional opportunity for mammalian cell banking is closely linked to whether new investments progress beyond fill-finish operations and into full upstream vaccine and biologics manufacturing.

 

Analyst Perspective: Where Are the Strongest Commercial Opportunities Emerging?

The mammalian cell banking market is shifting from basic cryopreservation to a more integrated GMP service model. Today, providers support the full workflow—from cell-line development to Master Cell Bank (MCB) and Working Cell Bank (WCB) creation, testing, regulatory release, and long-term storage. This reduces handling steps, improves consistency, and strengthens compliance across biologics manufacturing.

Growth is being driven by key segments. Working Cell Banks are expanding faster than Master Cell Banks due to repeated production needs, while HEK293 cells are gaining traction in viral-vector and gene-therapy manufacturing. Gene therapy and cell therapy are the fastest-growing applications, reflecting rising demand beyond traditional monoclonal antibodies. CDMOs are also the fastest-growing end users as more companies outsource complex biologics production.

Operational improvements are supporting this expansion. Automated and closed systems are increasingly used to reduce contamination risk and improve reproducibility in cell banking. At the same time, redundant and long-term storage is becoming more important, supported by regulatory expectations such as FDA guidance recommending multiple storage sites for critical cell banks to ensure continuity.

Overall, the market is evolving into a full biologics lifecycle service industry. CHO-based monoclonal antibody production remains the largest base, while HEK293 systems, advanced therapies, outsourcing to CDMOs, automation, and secure storage are driving the next phase of growth through 2032.

 

Mammalian Cell Banking Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 580 Million
Revenue Forecast in 2032	USD 1.47 Billion
Overall Growth Rate	CAGR of 14.2% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Cell Bank Type, By Cell Type, By Application, By End User, By Geography
By Cell Bank Type	Master Cell Bank, Working Cell Bank
By Cell Type	CHO Cells, HEK293 Cells, BHK Cells, Hybridoma Cells, Other Mammalian Cell Lines
By Application	Monoclonal Antibody Production, Vaccine Production, Gene Therapy, Cell Therapy, Recombinant Protein Production, Research and Development
By End User	Pharmaceutical and Biotechnology Companies, Contract Development and Manufacturing Organizations, Contract Research Organizations, Academic and Research Institutes
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	- Rising biologics and biosimilar manufacturing activity requiring qualified cell substrates- Increasing outsourcing of GMP cell banking services to specialized CDMOs and testing providers- Growing adoption of mammalian expression systems for monoclonal antibodies, vaccines, and advanced therapies
Customization Option	Available upon request